Bicyclic peptide oligonucleotide conjugates
AssigneesSarepta Therapeutics, Inc., Massachusetts Institute of Technology
InventorsJustin M. WOLFE, Colin M. FADZEN, Rebecca L. HOLDEN, Monica YAO, Gunnar J. HANSON, Bradley L. PENTELUTE
Life of this patent
Estimating the term…
Abstract
Provided herein are oligonucleotides, bicyclic peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
Claims26
A peptide-oligonucleotide conjugate of Formula I:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- A′ is selected from —NHCH2C(O)NH2, —N(C1-6-alkyl)CH2C(O)NH2,
- wherein
- R5 is —C(O)(O-alkyl)x-OH, wherein x is 3-10 and each alkyl group is independently at each occurrence C2-6-alkyl, or R5 is selected from —C(O)C1-6-alkyl, trityl, monomethoxytrityl, —(C1-6-alkyl)R6, —(C1-6-heteroalkyl)-R6, aryl-R6, heteroaryl-R6, —C(O)O—(C1-6-alkyl)-R6, —C(O)O-aryl-R6, —C(O)O-heteroaryl-R6, and
- wherein R6 is selected from OH, SH, and NH2, or R6 is O, S, or NH, covalently linked to a solid support;
- each R1 is independently selected from OH and —NR3R4, wherein each R3 and R4 are independently at each occurrence —C1-6-alkyl;
- each R2 is independently selected from H, a nucleobase, and a nucleobase functionalized with a chemical protecting-group, wherein the nucleobase independently at each occurrence comprises a C3-6-heterocyclic ring selected from pyridine, pyrimidine, triazinane, purine, and deaza-purine;
- z is 8-40;
- and
- E′ is selected from H, —C1-6-alkyl, —C(O)C1-6-alkyl, benzoyl, stearoyl, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl,
- wherein
- Q is —C(O)(CH2)6C(O)— or —C(O)(CH2)2S2(CH2)2C(O)—, and
- R7 is —(CH2)2OC(O)N(R8)2, wherein R8 is —(CH2)6NHC(═NH)NH2, and
- wherein L is covalently linked by an amide bond to the amino-terminus of J, and L is —C(O)(CH2)1-6—C1-6-heteroaromatic-(CH2)1-6C(O);
- t is 4-16;
- each J is independently at each occurrence selected from an amino acid of the structure
- wherein:
- r and q are each independently 0, 1, 2, 3, or 4;
- and
- each R9 is independently at each occurrence selected from H, an amino acid side-chain, and an amino acid side-chain functionalized with a protecting-group,
- wherein three or four amino acid side-chains of R9 independently at each occurrence comprise a sulfur atom:
- a) wherein when the number of sulfur atoms is three, then the sulfur atoms, together with the atoms to which they are attached, form the structure
- such that the amino acids form a bicyclic structure;
- or
- b) wherein when the number of sulfur atoms is four, then the sulfur atoms, together with the atoms to which they are attached, form two occurrences of the structure
- such that the amino acids form a bicyclic structure;
- wherein d is 0 or 1, and M is selected from:
- wherein each R10 is independently at each occurrence H or a halogen;
- and
- G is covalently linked by an amide bond to the carboxy-terminus of J, and G is selected from H, —C(O)C1-6-alkyl, benzoyl, and stearoyl, and
- wherein at least one of the following conditions is true:
(canceled)
(canceled)
-21. (canceled)
A modified peptide, wherein the modified peptide has one of the following structures:
- (SEQ ID NO. 7)
- CRRRRRRCRRRRRRC,
- (SEQ ID NO. 8)
- CRRRCRRRC,
- or
- (SEQ ID NO. 9)
- CRRRRRRCCRRRRRRC,
- wherein the peptide is capable of being attached to a polymorpholino oligonucleotide directly or via a linker to the N-terminus of the peptide;
- each R is arginine;
- each C is cysteine;
- and
- the C-terminus is attached to —NH2.
Dependencies are inferred from the claim text.